Should the dose of antituberculosis drugs be reduced in patients with liver disease?
D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D008107:Liver Diseases / Q000150:complications*; D012293:Rifampin / Q000008:administration & dosage*; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*
D007538:Isoniazid; D012293:Rifampin